Moderate to Severe Hot Flashes in Menopause: What to Do When Non-Hormonal Prescription Medications Have Not Controlled Symptoms

Clinical Scenario

This protocol applies to women in menopause who are experiencing moderate to severe hot flashes (vasomotor symptoms), do not have a uterus, and have no contraindication to estrogen therapy. Despite prior treatment, vasomotor symptoms remain at a clinically significant level.

Previous Treatment — Inadequate Response

The prior step involved non-hormonal prescription medications — including agents such as venlafaxine, desvenlafaxine, paroxetine, citalopram, escitalopram, gabapentin, pregabalin, and clonidine — with the treatment goal of reducing vasomotor symptoms (hot flashes). This protocol is indicated when that goal has not been adequately met.

Next-Line Approach (Partial Overview)

Management in this setting incorporates a structured psychological and behavioural intervention targeting the reduction of hot flash frequency and severity. The complete evidence-based regimen is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

Moderate to severe hot flashes: MHT is the gold standard and best therapy for reduction of VMS (Tables 1-5), followed by non-hormonal prescription medications (Tables 6, 7) as a second choice.

Women without a uterus can use systemic estrogen-alone therapy (ET).

Cognitive behavioural therapy may be helpful.

Cognitive behavioural therapy and, to a lesser extent, clinical hypnosis have been shown to be effective in reducing vasomotor symptoms.

View source ↗